Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004102
Status:
COMPLETED
Last Update Posted:
2011-03-28
First Post:
1999-12-10
Brief Title:
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Sponsor:
NYU Langone Health
Organization:
NYU Langone Health
Study Overview
Official Title:
A Phase II Trial of Eloxatin in Combination With 5-Fluorouracil and Leucovorin in Patients With Advanced Colorectal Carcinoma
Status:
COMPLETED
Status Verified Date:
2011-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die Combining more than one drug may kill more tumor cells Leucovorin may increase the effectiveness of fluorouracil by making tumor cells more sensitive to the drug
PURPOSE Phase II trial to study the effectiveness of combination chemotherapy consisting of oxaliplatin fluorouracil and leucovorin in treating patients who have colorectal cancer
PURPOSE Phase II trial to study the effectiveness of combination chemotherapy consisting of oxaliplatin fluorouracil and leucovorin in treating patients who have colorectal cancer
Detailed Description:
OBJECTIVES I Evaluate the quantitative and qualitative toxicities of oxaliplatin combined with fluorouracil and leucovorin calcium in patients with advanced adenocarcinoma of the colon or rectum
OUTLINE Patients receive leucovorin calcium IV over 10-20 minutes followed within 10 minutes by fluorouracil IV bolus on days 1 8 15 29 36 and 43 Patients receive oxaliplatin IV over 2 hours prior to leucovorin calcium and fluorouracil on days 1 15 29 and 43 Treatment repeats every 8 weeks for 3 courses in the absence of disease progression or unacceptable toxicity Patients with stable or responding disease may receive additional courses upon approval by the sponsor Patients are followed at 30 days
PROJECTED ACCRUAL A total of 18-35 patients will be accrued for this study
OUTLINE Patients receive leucovorin calcium IV over 10-20 minutes followed within 10 minutes by fluorouracil IV bolus on days 1 8 15 29 36 and 43 Patients receive oxaliplatin IV over 2 hours prior to leucovorin calcium and fluorouracil on days 1 15 29 and 43 Treatment repeats every 8 weeks for 3 courses in the absence of disease progression or unacceptable toxicity Patients with stable or responding disease may receive additional courses upon approval by the sponsor Patients are followed at 30 days
PROJECTED ACCRUAL A total of 18-35 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| P30CA016087 | NIH | None | None |
| NYU-9863 | None | None | None |
| SANOFI-EFC7132 | None | None | None |
| NCI-G99-1593 | US NIH GrantContract | None | httpsreporternihgovquickSearchP30CA016087 |